Select therapeutic use:
Indications for ELLA:
Prevention of pregnancy following unprotected intercourse or known or suspected contraceptive failure. Not for use as regular contraceptive.
Take 1 tab as soon as possible within 120hrs (5 days) after unprotected intercourse or contraceptive failure. May repeat dose if vomiting occurs within 3hrs.
Premenarchal: not applicable.
Not for termination of an existing pregnancy. Exclude pregnancy before prescribing. Rule out ectopic pregnancy if lower abdominal pain occurs. Rule out pregnancy if subsequent menses delayed by >1 week. Does not protect against HIV or other STDs. Repeat use within same menstrual cycle: not recommended. Nursing mothers.
Avoid concomitant CYP3A4 inducers (eg, barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, topiramate, St. John's wort). Potentiated by CYP3A4 inhibitors (eg, ketoconazole, itraconazole). May antagonize regular hormonal contraceptives; use barrier contraception for remainder of menstrual cycle and resume oral contraceptives ≥5 days after dose.
Headache, abdominal pain, nausea, dysmenorrhea, fatigue, dizziness; menstrual cycle changes.